Ignite Creation Date:
2024-05-06 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06199115
Status:
RECRUITING
Last Update Posted:
2024-01-10
First Post:
2023-12-21
Brief Title:
Prevention of Neuropathic Pain From Oxaliplatin by Photobiomodulation
Sponsor:
Saint-Gregoire Private Hospital Center
Organization:
Saint-Gregoire Private Hospital Center
Study Overview
Official Title:
Prevention of Neuropathic Pain From Oxaliplatin by Photobiomodulation
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Peripheral neuropathy is one of the most common side effects of oxaliplatin OXA-based chemotherapy for patients treated for digestive cancers disabling and dose-limiting Several strategies have been studied for the treatment of oxaliplatin-related sensory neuropathy Several pharmacological and non-pharmacological therapeutic strategies have been explored to relieve peripheral neuropathic pain Non-pharmacological interventions have been shown to be potentially beneficial for patients suffering from chemotherapy-induced neurotoxicity The objective of this prospective study is to evaluate the effectiveness of photobiomodulation on the reduction of neuropathic pain in patients who developed painful cumulative peripheral neuropathy that appeared under the effect of the treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None